

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re patent of:** Heinrich *et al.*

**Patent No.** 7,595,154

**Issued:** September 29, 2009

**Application No.** 10/517,905

**Filed:** December 10, 2004

**Confirmation No.** 4619

**For:** METHOD OF DETECTING A NEOPLASIA  
ASSOCIATED WITH AN ACTIVATING PLATELET  
DERIVED GROWTH FACTOR RECEPTOR ALPHA  
(PDGFRA) MUTATION

**FILED VIA EFS**

**Examiner:** Zachary C. Howard

**Art Unit:** 1646

**Attorney Reference No.** 899-65892-02

FILED VIA ELECTRONIC FILING SYSTEM  
COMMISSIONER FOR PATENTS

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

In Section 56 "Reference Cited", under "Other Publications":

Page 2, Column 1, Debiec-Rychter *et al.*, "studies" should be --studies--.

Page 2, Column 1, Gari *et al.*, "proto-ocogene" should be --proto-oncogene--.

Page 2, Column 1, Heinrich *et al.* (first entry), "alternations" should be --alterations--.

Page 2, Column 2, Madani *et al.*, "28-21" should be --18-21--.

Page 2, Column 2, Gleevec<sup>TM</sup>..., "gove/" should be --gov/--.

In the Specification:

Column 2, Line 2, "1052" should be --344--.

Column 3, Lines 10-11, "system Sample" should be --system. Sample--.

Column 3, Line 18, "18174R" should be --181874R--.

Column 3, Line 52, "would identifiable" should be --would be identifiable--.

Column 3, Line 58, "DGFRA" should be --PDGFRA--.

Column 3, Line 61, “phosphor-tyrosine” should be --phospho-tyrosine--.

Column 5, Line 16, “protein SEQ ID NO: 25” is missing a return, and should be --protein.

SEQ ID NO: 25-- (new paragraph).

Column 6, Line 48, “to” should be --two--.

Column 6, Line 54, “target The” should be --target. The--.

Column 7, Line 27, “ingredient The” should be --ingredient. The--.

Column 9, Line 11, “tract Generally” should be --tract. Generally--.

Column 9, Line 55, “or increased or increased” should be --or increased or decreased”.

Column 10, Line 53, “sequences.” should be --sequence--.

Column 11, Line 20, “term Thus” should be --term. Thus--.

Column 11, Line 48, “art Various” should be --art. Various--.

Column 12, Line 12, “T<sub>m</sub>” should be --T<sub>m</sub>--.

Column 13, Line 2, “F(ab')<sub>2</sub>” should be -- F(ab')<sub>2</sub>--.

Column 13, Line 18, “effectively oligonucleotide” should be --effective oligonucleotide(s)--.

Column 14, Line 15, “thereof comprising including” should --thereof including--.

Column 14, Line 46, “agent In” should be --agent. In--.

Column 14, Line 55, “fragments” should be --fragment--.

Column 16, Line 7, “shown in shown in” should be --shown in--.

Column 17, Line 60, “& and” should be --&--.

Column 18, Line 8, “immunaffinity” should be --immunoaffinity--.

Column 18, Line 27, “imatimb” should be --imatinib--.

Column 18, Line 38, “TK1” should be --TKI--.

Column 19, Line 24, “3140” should be --31-40--.

Column 19, Line 31, “TK1” should be --TKI--.

Column 20, Line 1, “CSF-LR” should be --CSF-1R--.

Column 21, Lines 41-42, “neoplasia In” should be --neoplasia. In--.

Column 25, Line 9, “CSF1-R” should be --CSF-1R--.

Column 25, Line 39, “aprotinin 10 µg” should be --aprotinin, 10 µg--.

Column 26, Line 66, “181874R The” should be --181874R. The--.

Column 29, Line 8, “PDGRA” should be --PDGFRA--.

Column 31, Lines 35-36, “Nildforov” should be --Nikiforov--.

Column 34, Line 30, "1998." should be --1998)--.

Column 39, Line 29, "adjuvant Also" should be --adjuvant. Also--.

Column 40, Line 13, "ant-PDGFR" should be --anti-PDGFRA--.

Column 40, Line 47, "SE ID NO: 10 positions" should be --SEQ ID NO: 10, positions--.

Column 45, Line 66, "sequence the" should be --sequence of the --.

Column 46, Line 63, "PDGR-A" should be --PDGFRA--.

Column 47, Line 29, "E1561" should be --ER561--.

Column 49, Line 34, "(86:4603-4611" should be --(*Blood* , 86:4603-4611--.

Column 50, Line 1, "determine" should be --determined--.

Column 51, Line 21, "Thr202Thr204" should be --Thr202/Thr204--.

Column 51, Line 24, "Y701, (Zymed" should be --Y701 (Zymed--.

Since not all of the errors are attributable to the Patent Office, the fee of \$100.00 pursuant to 37 C.F.R. 1.20(a) is submitted herewith via EFS. The preceding corrections remedy mistakes of a typographical nature and/or minor character. A proposed Certificate of Correction is provided herewith to make formal notice of the errors in the referenced patent. Applicants request that the Patent Office provide a formal Certificate of Correction to correct the errors noted herein.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301  
cc: Docketing

By /Tanya M. Harding/  
Tanya M. Harding, Ph.D.  
Registration No. 42,630